Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis

Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2 alpha signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2 alpha, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2 alpha-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2 alpha. Intestine HIF-2 alpha inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2 alpha regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2 alpha could be a viable target for hepatic steatosis therapy.